AU2013277217B2 - Methods of treating or preventing periodontitis and diseases associated with periodontitis - Google Patents

Methods of treating or preventing periodontitis and diseases associated with periodontitis Download PDF

Info

Publication number
AU2013277217B2
AU2013277217B2 AU2013277217A AU2013277217A AU2013277217B2 AU 2013277217 B2 AU2013277217 B2 AU 2013277217B2 AU 2013277217 A AU2013277217 A AU 2013277217A AU 2013277217 A AU2013277217 A AU 2013277217A AU 2013277217 B2 AU2013277217 B2 AU 2013277217B2
Authority
AU
Australia
Prior art keywords
weeks
control
compound
pct
periodontitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013277217A
Other languages
English (en)
Other versions
AU2013277217A1 (en
AU2013277217A2 (en
Inventor
George HAJISHENGALLIS
John D. Lambris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of AU2013277217A1 publication Critical patent/AU2013277217A1/en
Publication of AU2013277217A2 publication Critical patent/AU2013277217A2/en
Assigned to THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA reassignment THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Amend patent request/document other than specification (104) Assignors: George Hajishengallis, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
Application granted granted Critical
Publication of AU2013277217B2 publication Critical patent/AU2013277217B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/18—Dental and oral disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
AU2013277217A 2012-06-20 2013-06-19 Methods of treating or preventing periodontitis and diseases associated with periodontitis Active AU2013277217B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261662022P 2012-06-20 2012-06-20
US61/662,022 2012-06-20
US13/801,096 US9579360B2 (en) 2012-06-20 2013-03-13 Methods of treating or preventing periodontitis and diseases associated with periodontitis
US13/801,096 2013-03-13
PCT/US2013/046599 WO2013192319A1 (en) 2012-06-20 2013-06-19 Methods of treating or preventing periodontitis and diseases associated with periodontitis

Publications (3)

Publication Number Publication Date
AU2013277217A1 AU2013277217A1 (en) 2015-01-22
AU2013277217A2 AU2013277217A2 (en) 2015-01-22
AU2013277217B2 true AU2013277217B2 (en) 2018-03-08

Family

ID=49769337

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013277217A Active AU2013277217B2 (en) 2012-06-20 2013-06-19 Methods of treating or preventing periodontitis and diseases associated with periodontitis

Country Status (8)

Country Link
US (2) US9579360B2 (https=)
EP (1) EP2863949B1 (https=)
JP (1) JP6363595B2 (https=)
CN (1) CN104640567A (https=)
AU (1) AU2013277217B2 (https=)
CA (1) CA2877299C (https=)
IN (1) IN2015DN00438A (https=)
WO (1) WO2013192319A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110229216B (zh) 2011-09-07 2023-06-16 宾夕法尼亚州大学理事会 具有改善的药代动力学性质的坎普他汀类肽
US9579360B2 (en) * 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
HRP20200182T1 (hr) 2014-02-25 2020-05-01 Achillion Pharmaceuticals, Inc. Aril, heteroaril i heterociklični spojevi za liječenje komplementom posredovanih poremećaja
AU2015274482B2 (en) 2014-06-12 2018-11-08 Ucb Holdings, Inc. Modulation of complement activity
EP3250230B9 (en) 2015-01-28 2022-02-23 RA Pharmaceuticals, Inc. Modulators of complement activity
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
EP3359555B1 (en) 2015-10-07 2023-12-20 Apellis Pharmaceuticals, Inc. Dosing regimens
ES2941640T3 (es) 2015-12-16 2023-05-24 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento
MX2019006527A (es) 2016-12-07 2019-08-01 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
CN110603252A (zh) 2017-03-01 2019-12-20 艾其林医药公司 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
US20190038623A1 (en) 2017-08-02 2019-02-07 Achillion Pharmaceuticals, Inc. Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
BR112020010916A2 (pt) 2017-12-04 2020-11-17 Ra Pharmaceuticals, Inc moduladores da atividade do complemento
AU2018386304B2 (en) 2017-12-15 2023-12-07 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
EP3645550B1 (en) 2018-04-06 2021-11-03 The Trustees Of The University Of Pennsylvania Compstatin analogs with increased solubility and improved pharmacokinetic properties
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
US11814363B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Morphic forms of danicopan
BR112021005506A2 (pt) 2018-09-25 2021-06-15 Achillion Pharmaceuticals, Inc. formas mórficas de inibidores de fator complementar d
KR20210104071A (ko) 2018-12-17 2021-08-24 아칠리온 파르마세우티칼스 인코포레이티드 보체 매개 장애의 치료를 위한 표적 투약
EP3934675A2 (en) 2019-03-08 2022-01-12 RA Pharmaceuticals, Inc. Zilucoplan as deep tissue penetrating c5 inhibitor
WO2020198062A1 (en) 2019-03-22 2020-10-01 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
CA3134614A1 (en) 2019-03-29 2020-10-08 Ra Pharmaceuticals, Inc. Complement modulators and related methods
BR112021017820A2 (pt) 2019-04-24 2022-02-08 Ra Pharmaceuticals Inc Composições e métodos para modulação da atividade de complemento
CN113966224A (zh) 2019-06-04 2022-01-21 Ra制药公司 采用补体抑制剂的炎性疾病治疗

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100166862A1 (en) * 2007-02-05 2010-07-01 Potentia Pharmaceuticals, Inc. Local Complement Inhibition for Treatment of Complement-Mediated Disorders
WO2010132954A1 (en) * 2009-05-21 2010-11-25 Oral Health Australia Pty Ltd Method of treating periodontal disease by administering antagonists of par-2
WO2011091366A2 (en) * 2010-01-22 2011-07-28 University Of Louisville Research Foundation, Inc. Methods of treating or preventing periodontitis and diseases associated with periodontitis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270365A (en) 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US5627264A (en) * 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
JP2001294536A (ja) * 2000-04-12 2001-10-23 Sunstar Inc 歯周病予防・治療剤
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
ES2524922T3 (es) * 2005-05-10 2014-12-15 Intermune, Inc. Derivados de piridona para modular el sistema de proteína cinasa activada por estrés
WO2010056399A1 (en) * 2008-11-17 2010-05-20 Incode Biopharmaceutics, Inc. Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors
PL2424557T3 (pl) * 2009-05-01 2018-04-30 The Trustees Of The University Of Pennsylvania Zmodyfikowana kompstatyna z modyfikacjami szkieletu peptydowego i c-końca
JP5675821B2 (ja) * 2009-09-23 2015-02-25 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレート Ｔｏｌｌ様受容体モジュレーター及びその使用
WO2011115225A1 (ja) * 2010-03-17 2011-09-22 国立大学法人 鹿児島大学 歯周病特異的ペプチド、並びにそれを用いた歯周病の治療および診断
CN103796667A (zh) * 2011-06-22 2014-05-14 艾普莱斯制药公司 用补体抑制剂治疗慢性障碍的方法
CN110229216B (zh) * 2011-09-07 2023-06-16 宾夕法尼亚州大学理事会 具有改善的药代动力学性质的坎普他汀类肽
US9579360B2 (en) * 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100166862A1 (en) * 2007-02-05 2010-07-01 Potentia Pharmaceuticals, Inc. Local Complement Inhibition for Treatment of Complement-Mediated Disorders
WO2010132954A1 (en) * 2009-05-21 2010-11-25 Oral Health Australia Pty Ltd Method of treating periodontal disease by administering antagonists of par-2
WO2011091366A2 (en) * 2010-01-22 2011-07-28 University Of Louisville Research Foundation, Inc. Methods of treating or preventing periodontitis and diseases associated with periodontitis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HAJISHENGALLIS, G., "Complement and periodontitis", BIOCHEMICAL PHARMACOLOGY, (2010), vol. 80, pages 1992 - 2001 *

Also Published As

Publication number Publication date
WO2013192319A1 (en) 2013-12-27
US20170202935A1 (en) 2017-07-20
EP2863949B1 (en) 2019-01-23
CA2877299A1 (en) 2013-12-27
CA2877299C (en) 2022-07-12
IN2015DN00438A (https=) 2015-06-19
EP2863949A1 (en) 2015-04-29
US20130344082A1 (en) 2013-12-26
CN104640567A (zh) 2015-05-20
AU2013277217A1 (en) 2015-01-22
JP6363595B2 (ja) 2018-07-25
US10668135B2 (en) 2020-06-02
EP2863949A4 (en) 2016-03-02
US9579360B2 (en) 2017-02-28
AU2013277217A2 (en) 2015-01-22
JP2015523999A (ja) 2015-08-20

Similar Documents

Publication Publication Date Title
AU2013277217B2 (en) Methods of treating or preventing periodontitis and diseases associated with periodontitis
US20220025028A1 (en) Methods of Treating or Preventing Periodontitis and Diseases Associated with Periodontitis
Hajishengallis et al. Complement-dependent mechanisms and interventions in periodontal disease
US20050163764A1 (en) Treatment with agonists of toll-like receptors
Hajishengallis et al. Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application
WO2007122402A1 (en) Use of antagonists of cxcl13 or cxcr5 for treating wounds or fibrotic diseases
Kittaka et al. Alveolar bone protection by targeting the SH3BP2‐SYK axis in osteoclasts
Ma et al. Circadian rhythm disruption exacerbates the progression of macrophage dysfunction and alveolar bone loss in periodontitis
Tang et al. Dasatinib and Quercetin Mitigate Age‐Related Alveolar Bone Inflammaging and Neutrophil Infiltration
US20140302027A1 (en) Methods of treating periodontal inflammation and periodontal bone loss
CN102307586A (zh) 用于治疗自身免疫性疾病和炎性疾病的化合物及方法
US20100035829A1 (en) Method of treating intrauterine inflammation
Snipes et al. Inhibition of sphingosine‐1‐phosphate receptor 2 attenuated ligature‐induced periodontitis in mice
US20170136089A1 (en) Compositions and methods of regulating bone resorption
CA3044334A1 (en) Combined cd6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes
Moiré et al. Effects of dexamethasone on distribution and function of peripheral mononuclear blood cells in pneumonic calves
Kravets et al. FEATURES OF ANESTESIA PROVISION IN MAXILLO-FACIAL SURGERY IN PATIENTS WITH COMPLICATED MEDICAL HISTORY
Chen et al. Non‐Syndromic Hereditary Gingival Fibromatosis Driven by Chymase Deficiency Is Attenuated by Verteporfin‐Loaded Exosomes
Alshabab RANKL From Osteocytes Contributes to Periodontal Bone Loss
Rittling Evaluation of αlphav integrin role in mouse model induced periapical periodontitis
Allahem Evaluation of αLphav Integrin Role in Mouse
Pacios Pujadó Cellular mechanisms that affect periodontal destruction induced by bacteria infection in diabetic and non diabetic rats
Geis REGULATORY T CELLS PROMOTE IL-17-DEPENDENT CARCINOGENIC IMMUNITY TO ENTEROTOXIGENIC BACTEROIDES FRAGILIS
JP2015510887A (ja) 化膿性鼻副鼻腔炎の処置のためのチモシンαの使用

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 10 DEC 2014

HB Alteration of name in register

Owner name: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

Free format text: FORMER NAME(S): GEORGE HAJISHENGALLIS; UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.; THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

FGA Letters patent sealed or granted (standard patent)